{"url_path":"/sec/slxn/8-k/2026-07-21/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-003551-index.html","accession_number":"0001178913-26-003551","cik":"0002022416","ticker":"SLXN","issuer_name":"Silexion Therapeutics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-003551-index.html","primary_entity_key":"0002022416","primary_entity_name":"Silexion Therapeutics Corp"},"word_count":481,"has_tables":true,"body_markdown":"Item 5.07. Submission of Matters to a Vote of Security Holders.\n\n \n\nOn July 20, 2026, the Company reconvened the Meeting, which had been adjourned on July 13, 2026 due to the absence of a\nquorum. At the reconvened Meeting, holders of an aggregate of 230,276 ordinary shares, par value US$0.135 per share (“ordinary shares”), representing approximately 21.7% of the Company’s issued and outstanding ordinary shares, were present either in person or by proxy. Pursuant to Article 21.3 of the\nCompany’s amended and restated articles of association (the “Articles”), following the lapse of a half hour from the scheduled commencement time of\nthe reconvened Meeting, and in the absence of a quorum (defined as the presence of shareholders holding a majority of the Company’s issued and outstanding ordinary shares), the shareholders then present constituted a quorum for the purpose of\ntransacting business at the Meeting.\n\nAt the reconvened Meeting, the Company’s shareholders voted on the following proposals:\n\n(i)\n\nProposal 1: The approval of the\nexercisability of the (i) 399,020 aggregate new Series C ordinary warrants and Series D ordinary warrants to purchase 399,020 ordinary shares at an exercise price of $5.00 per ordinary share, and (ii) 13,966 placement agent warrants to\npurchase 13,966 ordinary shares at an exercise price of $6.25 per ordinary share, that the Company issued pursuant to the induced warrant exercise transaction that the Company completed on May 18, 2026 (all of such numbers of new warrants,\nplacement agent warrants, and underlying ordinary shares, and exercise prices and par value, have been adjusted to reflect the 1-for-10 reverse share split effected by Silexion on May 28, 2026) (the “New Warrant Exercisability Proposal”).\n\nThe result of the vote on the New Warrant Exercisability Proposal was as follows:\n\nNumber of Votes and % of Votes in Favor\n\n(Excluding Abstentions)\n\n \n\nNumber of Votes and % of Votes Against\n\n(Excluding Abstentions)\n\n \n\nAbstentions\n\n214,091 (93.3%)\n\n \n\n15,293 (6.7 %)\n\n \n\n892\n\n(ii)\n\nProposal 2: An increase to the\nauthorized share capital of the Company by 10,000,000 ordinary shares, from US$796,500 divided into 5,900,000 ordinary shares of a par value of US$0.135 each (which is the Company’s current authorized share capital following the 1-for-10\nreverse share split effected on May 28, 2026), to US$2,146,500 divided into 15,900,000 ordinary shares of a par value of US$0.135 each (the “Authorized\n\nShare Capital Increase Proposal”).\n\nThe result of the vote on the Authorized Share Capital Increase Proposal was as follows:\n\nNumber of Votes and % of Votes in Favor\n\n(Excluding Abstentions)\n\n \n\nNumber of Votes and % of Votes Against\n\n(Excluding Abstentions)\n\n \n\nAbstentions\n\n205,551 (89.8%)\n\n \n\n23,382 (10.2%)\n\n \n\n1,343\n\nBased on the above vote results, both proposals were approved by a majority of the votes cast by shareholders as, being\nentitled to do so, voted in person or by proxy at the Meeting, thereby satisfying the requisite approval threshold set forth in the relevant provisions of the Articles for each such proposal."}